Burden of extraintestinal manifestations and comorbidities in treated and untreated ulcerative colitis and Crohn’s disease : a Latvian nationwide prescription database study 2014–2019

Simple item page
dc.contributor.authorTeterina, Irēna
dc.contributor.authorMokricka, Viktorija
dc.contributor.authorPetrošina, Eva
dc.contributor.authorPokrotnieks, Juris
dc.contributor.institutionFaculty of Pharmacy
dc.contributor.institutionFaculty of Medicine
dc.date.accessioned2023-01-09T07:50:02Z
dc.date.available2023-01-09T07:50:02Z
dc.date.issued2022-12-01
dc.descriptionPublisher Copyright: © 2022 Irana Teterina et al., published by Sciendo.
dc.description.abstractInflammatory bowel diseases (IBD) are frequently accompanied by extraintestinal manifestations (EIMs) due to systemic autoimmune processes, which are important in the management of IBD patients and their long-term outcomes. The aim of the study was to determine the occurrence of EIMs comorbidities and their burden in IBD patients, based on the Latvian nationwide reimbursed prescription database from 2012 till 2019. Incident Crohn's disease (CD) and ulcerative colitis (UC) patients between 2014 and 2018 were matched on age and sex with non-treated IBD controls and followed up until 2019. EIMs were selected based on a previously used methodology and grouped into organ systems. The cohort was tested for differences in the timing and occurrence of EIMs, as well as overall cumulating disease burden. The study population included 187 CD and 1137 UC patients. Higher prevalence of EIMs was observed in untreated IBD patients, whereas in the treated IBD patient group prevalence remained numerically similar. Among treated patients, the most common EIMs affected cardiovascular, hepatopancreatobiliary, endocrine, musculoskeletal, respiratory, and the skin and intestinal tract systems, where 28.4-79.9% of IBD patients experienced these EIMs for the first time before their IBD diagnosis. The treated female IBD patients tended to have higher frequency of EIMs compared to male patients. The overall comorbidity burden trend increased with time. The study provides evidence that treated IBD patients have lower risk for EIMs/comorbidities compared to untreated IBD patients.en
dc.description.statusPeer reviewed
dc.format.extent10
dc.format.extent398191
dc.identifier.citationTeterina, I, Mokricka, V, Petrošina, E & Pokrotnieks, J 2022, 'Burden of extraintestinal manifestations and comorbidities in treated and untreated ulcerative colitis and Crohn’s disease : a Latvian nationwide prescription database study 2014–2019', Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences, vol. 76, no. 5/6, pp. 608-617. https://doi.org/10.2478/prolas-2022-0094
dc.identifier.doi10.2478/prolas-2022-0094
dc.identifier.issn1407-009X
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/10009
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85144334263&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofProceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectautoimmune disease
dc.subjectepidemiology
dc.subjectinflammatory bowel disease
dc.subjectNational Health Services and Central Statistics Bureau databases
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectGeneral
dc.titleBurden of extraintestinal manifestations and comorbidities in treated and untreated ulcerative colitis and Crohn’s disease : a Latvian nationwide prescription database study 2014–2019en
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
BURDEN_OF_EXTRAINTESTINAL_MANIFESTATIONS.pdf
Size:
388.86 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure